FINWIRES · TerminalLIVE
FINWIRES

Baiyunshan Pharmaceutical Gains China's Nod for Influenza Antiviral Suspension

By

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) branch entity, Baiyunshan Pharmaceutical General Factory, received drug registration from China's medical products regulator for oseltamivir phosphate for oral suspension.

The drug treats influenza A and B, according to a Tuesday filing with the Shanghai bourse.

Related Articles